Last reviewed · How we verify
NCT07060378
A Study of Contrast-enhanced EBUS in Lung Lesions and Intrathoracic Lymph Nodes
NA trial testing Contrast-enhanced endobronchial ultrasound in Lung Lesions in 250 participants. Currently enrolling.
30 December 2025
Quick facts
| Lead sponsor | Shanghai Chest Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 250 |
| Start date | 10 July 2025 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 January 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Contrast-enhanced endobronchial ultrasound
Conditions studied
- Lung Lesions — all drugs for Lung Lesions →
- Mediastinal and Hilar Lymph Node Enlargement — all drugs for Mediastinal and Hilar Lymph Node Enlargement →
Sponsor
Shanghai Chest Hospital
Who can join
Adults 18 to 90, any sex, with Lung Lesions or Mediastinal and Hilar Lymph Node Enlargement. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Exploring the Clinical Application Value of Contrast Enhancement Features in CE-EBUS Images for the Diagnosis of Pulmonary Lesions and Intrapulmonary Lymph Nodes
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07060378
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Lesions
Currently open trials in the same condition.
- NCT07006311 — Robotic-assisted Bronchoscopy Under Moderate Sedation With Propofol · NA · recruiting
Other Shanghai Chest Hospital trials
Trials by the same sponsor.
- NCT07515027 — Electroacupuncture Plus 5-HT3 Receptor Inhibitor for PONV Prevention in High-Risk Patients Undergoing Thoracoscopic Lung · NA · recruiting
- NCT07479628 — Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma · Phase 2 · not yet recruiting
- NCT07528066 — Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC · recruiting
- NCT07331727 — Epicardial Adipose Tissue-Targeted DApagliflozin for Reducing Electrical Remodeling in Atrial Fibrillation · NA · not yet recruiting
- NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07060378 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Chest Hospital
- Last refreshed: 11 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07060378.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing